Pharming Group N.V. Files 2023 Annual Report

Ticker: PHAR · Form: 20-F · Filed: 2024-04-04T00:00:00.000Z

Sentiment: neutral

Topics: annual-report, 20-F, pharmaceuticals

TL;DR

Pharming Group dropped its 2023 20-F, check it for the latest financials.

AI Summary

Pharming Group N.V. filed its 20-F for the fiscal year ending December 31, 2023. The company, based in Leiden, Netherlands, operates in the pharmaceutical preparations sector. The filing provides financial data and business updates for the reporting period.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Pharming Group's financial performance and business activities for 2023, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Pharming Group is subject to regulatory risks, clinical trial outcomes, and market competition, which can significantly impact its financial performance.

Key Numbers

2023-12-31 — Fiscal Year End (The period covered by the 20-F filing.)
2024-04-04 — Filing Date (The date the 20-F was submitted to the SEC.)

Key Players & Entities

Pharming Group N.V. (company) — Filer of the 20-F report
2023-12-31 (date) — Fiscal year end for the report
2024-04-04 (date) — Filing date of the report
Leiden (location) — City where Pharming Group is headquartered

FAQ

What is the primary business of Pharming Group N.V. as indicated in the filing?

Pharming Group N.V. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

What is the reporting period for this 20-F filing?

The Conformed Period of Report is for the fiscal year ending December 31, 2023.

Where is Pharming Group N.V. headquartered?

Pharming Group N.V. is headquartered at Darwinweg 24, Leiden, P7, 2333 CR.

When was the company's name last changed?

The company's former name was Pharming Group Group N.V., and the date of name change was October 14, 2020.

What is the SEC file number for Pharming Group N.V.?

The SEC file number for Pharming Group N.V. is 001-39822.

From the Filing

0001828316-24-000008.txt : 20240404 0001828316-24-000008.hdr.sgml : 20240404 20240404080300 ACCESSION NUMBER: 0001828316-24-000008 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 232 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240404 DATE AS OF CHANGE: 20240404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24821661 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 20-F 1 pharm-20231231.htm 20-F pharm-20231231 0001828316 2023 FY FALSE P1Y 5.0 1.0 2.5 10.0 2.0 5.0 2 5.0 1 10.0 1 2 0001828316 2023-01-01 2023-12-31 0001828316 dei:BusinessContactMember 2023-01-01 2023-12-31 0001828316 pharm:AmericanDepositarySharesMember 2023-01-01 2023-12-31 0001828316 ifrs-full:OrdinarySharesMember 2023-01-01 2023-12-31 0001828316 2023-12-31 xbrli:shares iso4217:USD 0001828316 2022-01-01 2022-12-31 0001828316 2021-01-01 2021-12-31 iso4217:USD xbrli:shares 0001828316 2022-12-31 0001828316 ifrs-full:IssuedCapitalMember 2020-12-31 0001828316 ifrs-full:SharePremiumMember 2020-12-31 0001828316 ifrs-full:OtherReservesMember 2020-12-31 0001828316 ifrs-full:RetainedEarningsMember 2020-12-31 0001828316 2020-12-31 0001828316 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001828316 ifrs-full:OtherReservesMember 2021-01-01 2021-12-31 0001828316 ifrs-full:IssuedCapitalMember 2021-01-01 2021-12-31 0001828316 ifrs-full:SharePremiumMember 2021-01-01 2021-12-31 0001828316 ifrs-full:IssuedCapitalMember 2021-12-31 0001828316 ifrs-full:SharePremiumMember 2021-12-31 0001828316 ifrs-full:OtherReservesMember 2021-12-31 0001828316 ifrs-full:RetainedEarningsMember 2021-12-31 0001828316 2021-12-31 0001828316 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001828316 ifrs-full:OtherReservesMember 2022-01-01 2022-12-31 0001828316 ifrs-full:IssuedCapitalMember 2022-01-01 2022-12-31 0001828316 ifrs-full:SharePremiumMember 2022-01-01 2022-12-31 0001828316 ifrs-full:IssuedCapitalMember 2022-12-31 0001828316 ifrs-full:SharePremiumMember 2022-12-31 0001828316 ifrs-full:OtherReservesMember 2022-12-31 0001828316 ifrs-full:RetainedEarningsMember 2022-12-31 0001828316 ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001828316 ifrs-full:OtherReservesMember 2023-01-01 2023-12-31 0001828316 ifrs-full:IssuedCapitalMember 2023-01-01 2023-12-31 0001828316 ifrs-full:SharePremiumMember 2023-01-01 2023-12-31 0001828316 ifrs-full:IssuedCapitalMember 2023-12-31 0001828316 ifrs-full:SharePremiumMember 2023-12-31 0001828316 ifrs-full:OtherReservesMember 2023-12-31 0001828316 ifrs-full:RetainedEarningsMember 2023-12-31 pharm:market xbrli:pure 0001828316 pharm:CapitalisedDevelopmentExpenditureRUCONESTForHAEEUMember 2023-01-01 2023-12-31 0001828316 pharm:RUCONESTLicenseForHAEUSMember 2023-01-01 2023-12-31 0001828316 pharm:RUCONESTLicenseForHAEEUMember 2023-01-01 2023-12-31 0001828316 pharm:JOENJALicenseForAPDSMember 2023-01-01 2023-12-31 0001828316 ifrs-full:BottomOfRangeMember ifrs-full:ComputerSoftwareMember 2023-01-01 2023-12-31 0001828316 ifrs-full:ComputerSoftwareMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001828316 ifrs-full:BottomOfRangeMember pharm:OperationalFacilitiesMember 2023-01-01 2023-12-31 0001828316 pharm:OperationalFacilitiesMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001828316 ifrs-full:BottomOfRangeMember ifrs-full:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001828316 ifrs-full:LeaseholdImprovementsMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001828316 ifrs-f